News about Drug Discovery & Development

Zydus Lifesciences to Launch Protection Against New Strain of Influenza Virus in India

Zydus is set to launch VaxiFlu-4, India’s first quadrivalent influenza vaccine of the season, formulated as per WHO’s 2025 southern hemisphere recommendations.

Drug Discovery & Development | 01/03/2025 | By Manvi

Eisai Signs Deal to Develop Tasurgratinib in Greater China Region with SciClone

Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions and continue to manufacture and market it in Japan, where it has been already launched.

Drug Discovery & Development | 01/03/2025 | By Aishwarya

BridGene Biosciences Signs Deal with Takeda to Discover Small Molecule Drugs

Under the terms of the collaboration, BridGene will use its chemoproteomics platform, IMTAC™, to discover novel small molecule drug candidates against challenging targets in immunology and neurology.

Drug Discovery & Development | 26/02/2025 | By Aishwarya

Tiziana Life Sciences Signs Deal for Product Development Services with Renaissance Lakewood

Under this agreement, Renaissance will use its extensive expertise in pharmaceutical-nasal product development and manufacturing to support the production of intranasal foralumab, ensuring compliance with the highest quality and regulatory requirements.

Drug Discovery & Development | 24/02/2025 | By Aishwarya

Biogen and Stoke Therapeutics to Develop and Commercialize Zorevunersen

Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome.

Drug Discovery & Development | 20/02/2025 | By Aishwarya

Innocan Pharma Secures its First Patent in India for its Liposomal CBD Injection

This granted patent protects Innocan's synthetic Cannabidiol-loaded Liposome Injection Platform (LPT-CBD), designed for precise dosing and sustained release of Synthetic CBD into the bloodstream.

Drug Discovery & Development | 19/02/2025 | By Aishwarya

Glenmark Pharmaceuticals Inc., USA Launches Clindamycin Phosphate Foam, 1 percent

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Clindamycin Phosphate Foam, 1 percent.

Drug Discovery & Development | 12/02/2025 | By Manvi

Hoth Therapeutics Collaborates with OnTargetx R&D Inc. to Advance Research for its Cancer-Fighting Therapeutic 'HT-KIT'

This immunohistochemistry study, conducted in partnership with Charles River Laboratories Montreal ULC, represents a key step in the preclinical development of HT-KIT.

Drug Discovery & Development | 11/02/2025 | By Manvi

Cosmo and Glenmark Receive UK MHRA Approval of Winlevi for Treatment of Acne

Winlevi® is a topical treatment for acne vulgaris in patients aged 12 years and older, marking a significant milestone in the commitment of both companies to providing innovative, patient-focused dermatology solutions.

Drug Discovery & Development | 10/02/2025 | By Aishwarya

Jupiter Neurosciences Signs JOTROL Manufacturing Agreement with Catalent

Under the terms of the agreement, Catalent will manufacture clinical batches of JOTROL, Jupiter’s proprietary resveratrol-based therapeutic, using an optimized softgel formulation.

Drug Discovery & Development | 04/02/2025 | By Aishwarya